Sökning: id:"swepub:oai:DiVA.org:uu-233794" >
Long-term complicat...
Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy
-
- von Bahr, Lena (författare)
- Karolinska Institutet
-
- Sundberg, Berit (författare)
- Karolinska Institutet
-
- Lönnies, Lena (författare)
- Karolinska Institutet
-
visa fler...
-
- Sander, Birgitta (författare)
- Karolinska Institutet
-
Karbach, Holger (författare)
-
- Hägglund, Hans (författare)
- Karolinska Institutet
-
- Ljungman, Per (författare)
- Karolinska Institutet
-
- Gustafsson, Britt (författare)
- Karolinska Institutet
-
Karlsson, Helen (författare)
-
- Le Blanc, Katarina (författare)
- Karolinska Institutet
-
- Ringdén, Olle (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2012
- 2012
- Engelska.
-
Ingår i: Biology of blood and marrow transplantation. - : Elsevier BV. - 1083-8791 .- 1523-6536. ; 18:4, s. 557-564
- Relaterad länk:
-
http://www.bbmt.org/...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Thirty-one patients treated with mesenchymal stromal cells (MSCs) for acute graft-versus-host disease (aGVHD) or hemorrhagic cystitis between 2002 and 2007 were followed to investigate predictors of outcome, immunologic effects in vivo, and long-term survival. There was no correlation between in vitro suppression by MSCs in mixed lymphocyte cultures and outcome. Soluble IL-2 receptors were measured in blood before and after MSC infusion and declined significantly during the first week after MSC infusion (P = .03). Levels of interleukin-6 and HLA-G were unaffected. Infectious complications occurred several years after recovery from aGVHD. Cytomegalovirus viral load was high, and cytomegalovirus disease was common. Among patients recovering from aGVHD, 54% died of late infections, between 4 months and 2 years after MSC treatment. No increase in leukemia relapse or graft rejection was found. Children had a better survival rate than adults (P = .005). In GVHD patients, 1-year survival was 75% in patients who received early-passage MSCs (from passages 1-2) in contrast to 21% using later passage MSCs (from passages 3-4) (P < .01). We conclude that treatment with early-passage MSCs improved survival in patients with therapy-resistant GVHD. Death from infection was common in MSC-treated patients, but there was no increase in leukemia relapse.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
von Bahr, Lena
-
Sundberg, Berit
-
Lönnies, Lena
-
Sander, Birgitta
-
Karbach, Holger
-
Hägglund, Hans
-
visa fler...
-
Ljungman, Per
-
Gustafsson, Brit ...
-
Karlsson, Helen
-
Le Blanc, Katari ...
-
Ringdén, Olle
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
Biology of blood ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet